Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05573984 · ClinicalTrials.gov registry record
Natural History of PRPF31 Mutation-Associated Retinal Dystrophy
A clinical trial of Retinitis Pigmentosa and Eye Diseases, Hereditary, sponsored by PYC Therapeutics.
- Active
- Registry status
- 50
- Enrollment target
- 7
- Study locations
NCT05573984 is a study of Retinitis Pigmentosa and Eye Diseases, Hereditary that is active but no longer recruiting, run by PYC Therapeutics. The registered enrollment target is 50 participants, below the 260-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (81% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT05573984, a study of Retinitis Pigmentosa and Eye Diseases, Hereditary, is active but no longer recruiting, sponsored by PYC Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to characterize the natural history through temporal systemic evaluation of subjects identified with PRPF31 mutation-associated retinal dystrophy, also called retinitis pigmentosa type 11, or RP11. Assessments will be completed to measure and evaluate structural and functional visual changes including those impacting patient quality of life associated with this inherited retinal condition and observing how these changes evolve over time.
Conditions Studied
Study Locations (7)
California
- University of California San Francisco - San Francisco
Florida
- University of Florida Health - Jacksonville
Michigan
- University of Michigan Kellogg Eye Center - Ann Arbor
Oregon
- Oregon Health and Science University - Casey Eye Institute - Portland
Texas
- Retina Foundation of the Southwest - Dallas
Western Australia
- Lions Eye Institute - Nedlands
Other
- Centre For Eye Research Australia (CERA) - Retinal Gene Therapy Unit - East Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-07-07 |
| Est. Completion | 2026-02-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05573984
The ClinicalTrials.gov registry entry for NCT05573984 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (81% lower). The listed sponsor is PYC Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 0 interventions.
NCT05573984 reports 7 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT05573984 about?
NCT05573984 is a clinical study titled "Natural History of PRPF31 Mutation-Associated Retinal Dystrophy". The purpose of this study is to characterize the natural history through temporal systemic evaluation of subjects identified with PRPF31 mutation-associated retinal dystrophy, also called retinitis pigmentosa type 11, or RP11. Assessments will be completed to measure and evaluate structural and fun...
What is the current status of trial NCT05573984?
This trial is currently active not recruiting. The enrollment target is 50 participants. The study started on 2022-07-07. Estimated completion is 2026-02-28.
What conditions does trial NCT05573984 study?
This clinical trial studies the following conditions: Retinitis Pigmentosa, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Dystrophy Rod, Retinal Dystrophy Rod Progressive.
Who is sponsoring clinical trial NCT05573984?
This trial is sponsored by PYC Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05573984 being conducted?
This trial has 7 study locations across California, Florida, Michigan, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Promising ROd-cone DYstrophy Gene therapY
RECRUITING · Phase 1
-
High Resolution Retinal Imaging
RECRUITING
-
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
RECRUITING · Phase 2
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
-
Retinal Imaging in Patients With Inherited Retinal Degenerations
RECRUITING
-
Cell Collection to Study Eye Diseases
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.